Human Metabolome Technologies Inc (HMT) is a company that values innovation, scientific excellence, and collaboration. Their corporate philosophy revolves around advancing metabolomics research through cutting-edge technology, high-quality services, and strategic partnerships. HMT is committed to revolutionizing healthcare by understanding metabolic processes and developing targeted solutions for diagnosis, treatment, and drug development. By leveraging their expertise in metabolomics, HMT aims to provide valuable insights into human health and enable personalized medicine. Through their relentless pursuit of scientific discovery and commitment to societal well-being, Human Metabolome Technologies Inc stands as a leader in the field of metabolomics and aims to improve global health outcomes.

Human Metabolome Technologies Inc (HMT) is primarily present in Japan. As a leading metabolomics company, HMT is headquartered in Tsuruoka, Yamagata. With a strong focus on advancing metabolomics research and technology, HMT has established a significant presence in Japan. Through its innovative metabolomics solutions and services, HMT contributes to the advancement of bioinformatics and the understanding of human metabolism.

Some significant milestones achieved by Human Metabolome Technologies Inc include its establishment in 2003, becoming a publicly listed company in 2012, and partnering with various global pharmaceutical companies to advance metabolomics research. The company has consistently expanded its product portfolio, offering innovative solutions for metabolomics analysis. Human Metabolome Technologies Inc has also received several awards and recognitions for its contributions to the field of metabolomics, highlighting its expertise and leadership in this area. These milestones demonstrate the company's commitment to advancing metabolomics research and its significant impact on medical and scientific communities worldwide.

Human Metabolome Technologies Inc (HMT) is a prominent company specializing in metabolomics research and analysis. Founded in 2003, HMT has become a leader in the field, revolutionizing our understanding of metabolic profiling and its applications. The company provides state-of-the-art technology and advanced solutions to identify and quantify small molecule metabolites, aiding in the research of various diseases and drug development. HMT's groundbreaking research and collaborations have resulted in numerous patents and publications, establishing their credibility in the scientific community. Today, HMT continues to expand its capabilities and contribute to advancements in metabolomics research, making significant contributions to personalized medicine and beyond.

The main competitors of Human Metabolome Technologies Inc in the market include Metabolon Inc, Biocrates Life Sciences AG, and Metanomics Health GmbH.

Human Metabolome Technologies Inc is primarily active in the biotechnology and pharmaceutical industries.

Human Metabolome Technologies Inc (HMT) operates based on a unique business model in the field of metabolomics. HMT mainly focuses on metabolome analysis, which involves the comprehensive study of small molecules within biological systems. By employing advanced technologies and analytical methods, HMT offers services related to metabolomics research, including metabolome analysis, biomarker research, and personalized medicine development. As a leader in the field, Human Metabolome Technologies Inc aims to unlock valuable insights into metabolic profiles, leading to breakthrough discoveries in medicine, nutrition, and diagnostics.

Human Metabolome Technologies KGV ir 14,59.

Human Metabolome Technologies KUV ir 2,64.

AlleAktien kvalitātes vērtējums Human Metabolome Technologies ir 5/10.

Human Metabolome Technologies apgrozījums ir 1,35 miljardi JPY.

Human Metabolome Technologies peļņa ir 243,25 milj. JPY.

The company Human Metabolome Technologies Inc (HMT) is a global leader in providing systems for the analysis of metabolites. HMT is headquartered in Japan and also operates branches in North America and Europe. The business model of HMT is to develop and offer innovative technologies for studying metabolic processes in biological systems. HMT focuses on three main areas: research and development, services, and products. The main goal of HMT is to enable a better understanding of metabolic processes in various biological systems, including human diseases. Research and Development HMT is a research company that focuses on the development of applications for analyzing human metabolism. The company utilizes state-of-the-art technologies and research findings to support the study of metabolic diseases, cancer, neurological disorders, and other medical conditions. HMT also engages in research collaborations with leading academic institutions and companies worldwide. Services The company also offers services to assist customers in the identification, quantification, characterization, and validation of metabolites in biological samples. HMT has developed a range of services that allow researchers and companies to investigate the metabolism of humans and animals in different states. HMT's services include: - Metabolome analysis - Bioinformatics analysis - Database services Metabolome analysis involves the quantitative analysis of metabolites in a biological sample. This analysis can be performed by HMT to investigate specific metabolic processes and identify disease-related changes. Bioinformatics analysis is the analysis of data from metabolome analyses. Mathematical algorithms are used to identify relationships between different metabolites and metabolic processes. Database services include access to HMT's metabolite-based databases, which provide access to metabolic pathway information, metabolic regulatory mechanisms, and disease-related metabolite profiles. Products HMT has developed a range of products that enable researchers and companies to investigate metabolic processes and perform metabolic analyses. HMT's product range includes: - LC-MS systems for metabolomic analysis of samples - Metabolite standards and reagents - Software and databases for the analysis of metabolic data HMT's LC-MS system is a powerful instrument for the quantitative analysis of metabolites in biological samples. The system is capable of identifying and quantifying hundreds of metabolites in a single sample. HMT's metabolite standards and reagents include a wide range of standard metabolites and isotopically labeled compounds. These products ensure precise and reliable analysis results. Conclusion HMT's business model encompasses research and development, services, and products that focus on the study of metabolites and metabolic processes in biological systems. HMT has established itself as a leading provider of metabolome analysis solutions and will continuously expand its product range to meet the needs of research institutions, pharmaceutical companies, biotechnology companies, and government agencies.

Human Metabolome Technologies izmaksā dividendes 0 JPY, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Human Metabolome Technologies vai uzņēmums nedod dividendes.

Human Metabolome Technologies ISIN ir JP3794530000.

Human Metabolome Technologies simbols ir 6090.T.

Pēdējo 12 mēnešu laikā Human Metabolome Technologies maksāja dividendes 15,00 JPY apmērā. Tas atbilst aptuveni 2,50 % dividendes ražībai. Nākamajos 12 mēnešos Human Metabolome Technologies plāno maksāt dividendes 15,00 JPY apmērā.

Human Metabolome Technologies pašreizējā dividendu rentabilitāte ir 2,50 %.

Human Metabolome Technologies maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Human Metabolome Technologies pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 15,00 JPY. Tas atbilst dividendes ražībai 2,50 %.

Human Metabolome Technologies tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Human Metabolome Technologies apmērā 15 JPY, kas tika izmaksāta 1.09.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 27.06.2024..

Pēdējās dividendes izmaksa notika 1.09.2024..

Gadā 2023, Human Metabolome Technologies izmaksāja 10 JPY dividendes.

Human Metabolome Technologies dividendes tiek izmaksātas JPY.